Diamyd Medical AB Class B

As of May 31, 2026, Diamyd Medical AB Class B carries a market capitalization of 173.27M, placing it among publicly traded companies globally. Its enterprise value stands at -172.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of May 31, 2026, Diamyd Medical AB Class B has 154.98M shares outstanding.

These figures are as of May 31, 2026.

As of May 31, 2026, Diamyd Medical AB Class B maintains a current ratio of 15.50, meaning it holds 15.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended May 31, 2026.

As of the close on October 22, 2026, Diamyd Medical AB Class B's stock has declined approximately 90.61% over the past 52 weeks. The 50-day moving average sits at 1.02, while the 200-day moving average is 4.97.

These figures are as of May 31, 2026. Total book value stands at 259.39M, with working capital of 329.46M providing operational flexibility.

These figures cover the twelve months ended May 31, 2026.

Diamyd Medical AB Class B's most recent stock split took place on April 10, 2025.